oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Celiac disease and risk of myasthenia gravis - nationwide population-based study
Department of Neurology, New York University School of Medicine, New York NY, United States.
Peripheral Neuropathy Center, Neurological Institute, Columbia University, College of Physicians and Surgeons, New York NY, United States.
Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York NY, United States; Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York NY, United States.
Show others and affiliations
2018 (English)In: BMC Neurology, ISSN 1471-2377, E-ISSN 1471-2377, Vol. 18, article id 28Article in journal (Refereed) Published
Abstract [en]

Background: Case reports suggest there may be an association between celiac disease (CD) and myasthenia gravis (MG).

Methods: We identified 29,086 individuals with CD in Sweden from 1969 to 2008. We compared these individuals with 144,480 matched controls. Hazard ratios (HRs) for future MG (identified through ICD codes) were estimated using Cox regression.

Results: During 326,376 person-years of follow-up in CD patients, there were 7 MG cases (21/million person-years) compared to 22 MG cases in controls during 1,642,273 years of follow-up (14/million person-years) corresponding to a HR of 1.48 (95% CI = 0.64-3.41). HRs did not differ when stratifying for age, sex or calendar period. HRs were highest in the first year after follow-up, though insignificant. Individuals with CD were at no increased risk of MG more than 5 years after CD diagnosis (HR = 0.70; 95% CI = 0.16-3.09).

Conclusion: This study found no increased risk of MG in patients with CD.

Place, publisher, year, edition, pages
BIOMED CENTRAL LTD , 2018. Vol. 18, article id 28
Keywords [en]
Autoimmune, Celiac, Gluten, Myasthenia gravis
National Category
Neurology
Identifiers
URN: urn:nbn:se:oru:diva-66265DOI: 10.1186/s12883-018-1035-2ISI: 000427138100001PubMedID: 29529996Scopus ID: 2-s2.0-85043477669OAI: oai:DiVA.org:oru-66265DiVA, id: diva2:1194568
Funder
Swedish Society of MedicineSwedish Research Council
Note

Funding Agency:

National Center for Advancing Translational Sciences, National Institutes of Health  UL1 TR000040

Available from: 2018-04-03 Created: 2018-04-03 Last updated: 2018-08-30Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Ludvigsson, Jonas F.

Search in DiVA

By author/editor
Ludvigsson, Jonas F.
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
BMC Neurology
Neurology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 40 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf